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Abstract 
Purpose: To investigate the effect of apigenin on Barrett's esophagus–associated esophageal 
adenocarcinoma (BEAC) cells OE33, and also to ascertain the mechanism by which it inhibits cellular 
proliferation and motility.  
Methods: Proliferation index of OE33 in the absence and presence of apigenin was determined by 
methyl-thiazolyl-tetrazolium (MTT) assay and apoptosis was determined by enzyme-linked 
immunosorbent assay (ELISA) method. Boyden Chamber’s assay was applied to determine the 
migration and invasion of control and apigenin-treated OE33 cells. Status of PI3K/Akt/mTor signaling 
was further determined by Western blotting in control and apigenin-treated cells.  
Results: Apigenin resulted in the inhibition of the proliferation of OE33 cells in a dose- and time-
dependent fashion, with an IC50 of 75 µM, after 72 h of incubation, and also induced apoptosis, with 
modulation of pro- and anti-apoptotic genes. Furthermore, apigenin inhibited the motility of OE33 by 
targeting PI3K/Akt/mTOR signaling.  
Conclusion: Apigenin effectively inhibits the oncogenicity of OE33 cells by targeting PI3K/Akt/mTOR 
pathway. 
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4H-1-benzo-pyran-4-one] is a dietary flavone, 
found abundantly in  fruits and variety of 
vegetables including parsley, oranges , onions,  
tea, chamomile, wheat sprouts, etc [1,2]. 
Apigenin has immense therapeutic potential due 
to its anti-inflammatory, antiviral, antimutagenic 
as well as anticancer properties [2-10]. In certain 
cancer cells, apigenin has been known to target 
the PI3K/Akt/mTOR signaling leading to inhibition 
of oncogenicity [11-14]. 
 
Barrett's esophagus–associated esophageal 
adenocarcinoma (BEAC) has become the fastest 
growing tumor in the western world, within the 
last three decades [15,16]. In the United States 
alone, the incidence of BEAC had increased by 
300 % to 500 % in the last 40 years [17] and 
recently published meta-analysis studies reveal 
that similar risk factors of Barrett's esophagus 
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also prevail in Asian countries [18]. Barrett’s 
esophagus (BE) is known to be the most 
significant precursor lesion for esophageal 
adenocarcinoma (EAC) [19], which resulted from 
the  longstanding exposure of the esophageal 
mucosa to gastro-esophageal reflux, resulting in 
the metaplastic replacement of the native 
squamous epithelia by columnar cells (i.e. 
Barrett’s mucosa) [20,21]. This epithelial 
population serves as the platform for the 
formation of intra-epithelial neoplasia, also 
termed as dysplasia, which thereafter might lead 
to the Barrett-related EAC [20,21]. 
 
Since the effect of apigenin on BAEC is not 
investigated previously, we conducted this 
research to find out whether apigenin can inhibit 
BAEC. For our study we have used esophageal 
adenocarcinoma cell line OE33, as the in vitro   
model and also investigated the mechanism of 






Apigenin was purchased from Sigma. Nutrient 
mixture Dulbecco’s minimal essential medium 
(supplemented with 1 mM L-glutamine), fetal 
bovine serum, penicillin-streptomycin, and 0.25 
% Trypsin-EDTA were purchased from GIBCO 
(Invitrogen). Primary antibodies such as Bax, and  
Bcl-2, were purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA, USA), 
whereas cleaved caspase-3, cleaved caspase-
9,PI3K (p85), p-Akt ( Ser473), and p-mTor 
(Ser2448) were purchased from Signaling 
Technologies (Beverly, MA, USA). 
 
Cell culture and maintenance 
 
BEAC cell line OE33, was purchased from 
American Type Culture Collection (ATCC). OE33 
cells used in this study were from fifth through 
tenth passages and were routinely maintained in 
Dulbecco's Modified Eagle's Medium  
supplemented with 10 % FBS and antibiotics , 
penicillin (100 U/mL), and streptomycin (100 
μg/mL), at 37 °C in a humidified chamber. 
 
Cell viability assay (MTT assay) 
 
Cultured OE33 cells were seeded in 96 well plate 
at a density of 1 × 104 cells/ml and grown to 
confluency. Cell were then treated with different 
concentrations of apigenin (0-100 µM) for 24, 48 
and 72 h, respectively.  After treatment, MTT 
solution was added to each well and the 
absorbance was measured on an ELISA reader 
(MultiskanEX, Lab systems, Helsinki, Finland) at 
a wavelength of 570 nm according to published 
protocol (29). Data are presented as percent 
inhibition, calculated as in Eq 1. 
 
Inhibition (%) = {100-(At-As)/100} …………… (1) 
 
where At and As are the absorbance of the test 




Involvement of apoptosis in apigenin treated 
OE33 cells was determined using the apoptosis 
detection ELISA kit (Roche Diagnostic, USA) 
following. Briefly, control and apigenin-treated 
cells were subjected to lysis and centrifuged at 
1500 x g for 15 min. The cytosolic supernatant 
was collected, and the total protein was 
estimated. Around 10 μg of protein, from each 
sample was added to streptavidin-coated well, 
containing 80 μL of reaction mixture consisting of 
anti-histone-biotin and anti-DNA–peroxidase and 
incubated for 2 h with continuous shaking. Finally 
the chromagenic substrate ABTS (2,2¢-azino-di-
(3-ethylbenzthiazoline-6-sulfonic acid)) was 
added into each well  to get a colored product, 
which  was measured by the ELISA reader at 
405 nm. 
 
Determination of migration/invasion by 
Boyden Chamber assay 
 
Migratory properties of OE33 cells were 
determined by Boyden chamber assay, using 
track-etched polyethylene terephthalate 
membranes (Corning, MA), with 8.0 μm 
diameter-pore size. OE33 cells were treated with 
apigenin (0 – 75 µM) for 48 h, and migration 
assay was performed accordingly. Invasion was 
performed following the published protocol, using 
Matrigel®-coated invasion chambers (BD 
Biosciences). The cells which migrated/ invaded 
to the lower surface of the membrane were 
stained with crystal violet. The resultant crystal 
violet complex was then dissolved in 10 % acetic 
acid and the absorbance was measured at 600 
nm, using the microplate reader (Multiskan EX, 
Lab systems, Helsinki, Finland) to determine the 
extent of migration or invasion. 
 
Western blot analysis 
 
Cultured OE33 cells after treatment with 
apigenin, were extracted in ice cold lysis buffer, 
constituted of 150 mM NaCl, 20 mM Tris-HCl, 1 
% NP-40, 20 μg/mL leupeptin, 20 μg/mL 
aprotinin, 1 mM ortho-vanadate, and 2 mM 
PMSF, pH 7.4. Total protein from the cell lysates 
were estimated by Bradford method. 
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Approximately, 30 - 50 μg of protein from each 
sample was separated by 10 - 12 % SDS-PAGE, 
electrophoretically transferred to polyvinylidene 
difluoride membrane, incubated with different 
monoclonal and polyclonal antibodies according 
to manufacturer’s mentioned dilution and 
subsequently with required secondary 
antibodies. Then, the membranes were exposed 





Analysis of data was achieved with GraphPad 
Prism version 4.00 (GraphPad Software, San 
Diego, California, USA). All data are expressed 
as mean ± SD. Statistically significant differences 
between groups were determined by paired 
Student's two-tailed t-test. P < 0.05 was 




Apigenin inhibits proliferation of OE33 cells 
 
Treatment of esophageal adenocarcinoma cells, 
OE33 with apigenin resulted in the decrease of 
cellular proliferation in both concentration and 
time-dependent fashion (Fig 1B). OE33 cells 
were treated with different concentrations of 
apigenin (0 - 100 µM) for 24, 48 and 72 h, 
respectively. A drastic reduction in the cell 
viability was observed after 72 h of treatment and 
the IC50 was observed at a concentration of 75 
µM apigenin (Figure 1). 
 
Apoptosis and modulation of pro-and anti-
apoptotic markers  
 
To find out the mode of cell death in apigenin-
treated OE33 cells we determined the 
involvement of apoptosis. In the presence of 50 
µM apigenin, apoptosis was increased by 2.4-
fold, while in presence of 75 µM apigenin, it was 
increased by 7.5-fold. Thus the results indicate 
that apigenin can induce apoptosis in OE33 cells 
in a concentration -dependent fashion (Figure 
2A). Moreover we also observed the status of 
Bax/Bcl-2 ratio in apigenin-treated OE33 cells. 
We observed that, the pro-apoptotic protein Bax 
is up regulated, while the anti-apoptotic protein 
Bcl-2 is down regulated, the increasing 
concentrations of apigenin (Figure 2B and Figure 
2C). Also significant up regulation of cleaved 
caspase-3 and caspase-9 were observed, 
suggesting that apigenin is activating the intrinsic 
apoptotic pathway in OE33 cells (Fig 2D and 2E). 
 
Figure 1: Inhibition of cell proliferation by apigenin. A. Chemical structure of apigenin. B.  Approximately 60-70 % 
confluent OE33 cells were grown in the presence or absence of different concentrations of apigenin (0-100 µM) 
for 24h, 48h and 72h respectively, and cellular viability/proliferation was determined using MTT assay. The 
results are expressed as mean ± standard deviation of three independent experiments 
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Figure 2: Induction of apoptosis and modulation of pro-and anti-apoptotic markers by apigenin. A. Apoptosis in 
OE33 cells, as determined using cell death detection ELISA kit. B. Expression of Bax, Bcl-2, cleaved caspase-3 
and caspase-9 in control and apigenin treated OE33 cells. C. Bax/ Bcl-2 ratio. D. Relative band intensities for 




Figure 3: Inhibition of in vitro migration/invasion of OE33 cells by apigenin. OE33 cells were treated with different 
concentration of apigenin (0-75 µM) for 72 h and extent of A. migration and B. invasion were determined by the 




Figure 4: Effect of apigenin on PI3K/Akt/mTOR pathway. OE33 cells were treated with different doses of 
apigenin (0-75 µM) for 72 h, harvested and cell lysates were subjected to western blot. A. Western blot analysis 
for PI3K (p85), p-Akt Ser 473, and p-mTor Ser 2448. β-actin was used as a loading control. B. Relative band intensities 
for PI3K (p85), p-Akt Ser 473, and p-mTor Ser 2448. The results are expressed as mean ± standard deviation of three 
independent experiments [*p<0.05 vs. apigenin-treated] 
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Apigenin inhibits the motility of OE33 cells 
 
Migratory or invasive properties of aggressive 
cancer cells are the hallmark of tumor 
metastasis. To find out whether, apigenin can 
inhibit the motility of OE33 cells we performed 
the migration as well invasion assays using the 
Boyden Chamber (Fig 3). Significant inhibition of 
cellular migration was observed at 50 µM 
apigenin (~33 %), while in presence of 75 µM 
apigenin, the migration was reduced by almost 
60 % (Fig 3A). Similar pattern was observed 
when invasion assay was performed with 
apigenin-treated cells and the invasive 
phenotype of OE33 cells were inhibited by 
apigenin in a concentration dependent fashion 
(Fig 3B). 
 
Apigenin inhibits the PI3K/Akt/mTOR pathway 
in OE33 cells. 
 
PI3K/Akt/mTOR signaling plays vital role in cell 
proliferation, growth and survival and is one of 
the pathways frequently activated in cancer, 
including BEAC [17-19]. Many anticancer agents 
act by down regulating this signaling pathway, 
thus promoting apoptosis in cancer cells (15, 16). 
To further explore the mechanism of cell death 
caused by apigenin, the expression and 
phosphorylation status of the components of this 
signaling pathway were analyzed (Fig 4). We 
observed that, apigenin- treatment caused 
significant reduction in p85, the regulatory 
subunit of PI3K and also reduced the expression 
of phosphorylated (Ser 473) form of Akt. The 
effect of apigenin on mTOR activity was further 
investigated and exposure of OE33 cells to 
apigenin resulted in decrease in the level of 
activated form of mTOR (phosphorylated form- 
Ser2448), although the total Akt and mTOR 
levels remained unaffected by the treatment 




The beneficial health effects of dietary 
phytochemicals have made them promising 
candidates for treatment and prevention of 
multiple diseases, including cancer. However, 
precise cellular and molecular targets for dietary 
supplements remain largely unknown. Apigenin 
is a dietary flavone, commonly associated with 
fruit- and vegetable-diets [1,2]. This dietary 
flavonoid has potential anticancer properties, but 
most importantly it has negligible adverse effects 
on noncancerous cell types. There was no earlier 
report of the mode of action of apigenin on 
esophageal adenocarcinoma or EAC. Hence in 
the present study we have investigated in detail, 
the mechanism by which apigenin imparts its 
growth inhibitory effect on EAC cells, OE33. 
 
It was observed that apigenin exhibits superior 
anticancer properties by inhibiting the cellular 
proliferation of OE33 cells in both concentration 
and time-dependent fashion. Further 
experimental evidences confirmed that, this 
dietary flavonoid is effective in inducing 
apoptosis in OE33, in a concentration dependent 
fashion. Expectedly the Bax/Bcl-2 ratio was 
found to increase with increased apigenin 
concentration, confirming the involvement of 
apoptosis in apigenin mediated cytotoxicity. 
Furthermore, it was observed that apigenin-
induced apoptosis is mediated by caspase-3 
dependent pathway. Since BEAC is highly 
metastatic in nature, we determined whether 
apigenin can inhibit the motility of OE33 cells. 
Very interestingly, we observed that, apigenin-
treatment resulted in the inhibition of both 
migratory as well as invasive properties of OE33 
cells in a concentration dependent fashion.  
 
Considering the important role of PI3K/Akt/mTor 
signaling in the advancement of BEAC, we 
investigated whether apigenin can block this 
pathway in OE33 cells. Our western blot data 
confirmed that, apigenin targets this oncogenic 
signaling pathway in OE33cells. Expression 
levels of p85, the regulatory subunit of PI3K, 
were drastically down regulated by apigenin in a 
concentration dependent fashion. Moreover the 
phosphorylation-dependent activation of the 
downstream modulators, such as p-Akt (Ser-473) 





The findings of the present study serve to 
delineate the anticancer mechanism of the 
dietary flavone, apigenin, against BEAC cells, 
which has the potential of a major therapeutic 
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